AGM
KYTX icon

Alpine Global Management’s Kyverna Therapeutics KYTX Stock Holding History

Alpine Global Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-16,169
Closed -$121K – 495
2024
Q2 		$121K Buy
+16,169
New +$247K 0.02% 382

Other funds holding KYTX

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Alpine Global Management's KYTX Position: Q3 2024 in Review

Alpine Global Management sold out of Kyverna Therapeutics (KYTX) in Q3 2024, closing a stake of 16,169 shares — an estimated $121K sold.

Alpine Global Management first reported a position in KYTX in Q2 2024 and held it in 1 quarter. The position peaked at $121K in Q2 2024. 94 funds tracked by Wall St. Rank hold KYTX as of Q3 2024.

  • Alpine Global Management reported no remaining Kyverna Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Alpine Global Management sold 16,169 Kyverna Therapeutics shares in Q3 2024, an estimated $121K.
  • Alpine Global Management first reported a position in Kyverna Therapeutics in Q2 2024 and held it in 1 quarter.
  • Alpine Global Management's Kyverna Therapeutics position peaked at $121K in Q2 2024.
  • 94 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q3 2024.

Based on Alpine Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.